Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antibody directed therapy for leukemia].

Akihiro Takeshita1, Kensuke Naito, Ryuzo Ohno

  • 1Laboratory Medicine, Hamamatsu University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 22, 2002
PubMed
Summary

Monoclonal antibody therapies targeting acute myeloid leukemia (AML) show promise. Combining gemtuzumab ozogamicin with multi-drug resistance modifiers may enhance its effectiveness against AML.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Aggressive non-nodal mantle cell lymphoma with challenging subtype classification at presentation].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same author

A Case of Acute Promyelocytic Leukemia with t(11;17)(q23.2;q21.2) Treated with Haploidentical Transplantation Using Post-Transplant Cyclophosphamide.

Internal medicine (Tokyo, Japan)·2026
Same author

Predictors of skeletal muscle loss during first-line therapy in diffuse large B-cell lymphoma: the Glasgow Prognostic Score.

BMJ supportive & palliative care·2025
Same author

Adverse events during preoperative autologous blood donation and its usage in obstetrical patients: A multicenter, retrospective survey in Japan.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2025
Same author

Long-Term Outcome of Eltrombopag With First-Line Immunosuppressive Therapy for Newly Diagnosed Severe Aplastic Anemia.

Journal of hematology·2024
Same author

A Nationwide Retrospective Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Hemophagocytic Lymphohistiocytosis.

Transplantation and cellular therapy·2024

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Monoclonal antibody (MoAb) therapies targeting myeloid leukemia cell antigens like CD33 are advancing.
  • Key MoAb therapies for acute myeloid leukemia (AML) include unconjugated, chemo/toxin-conjugated, and radioisotope-conjugated antibodies.

Purpose of the Study:

  • To review the efficacy of MoAb therapies in AML.
  • To explore the potential of combination therapy with multi-drug resistance (MDR) modifiers to overcome resistance to gemtuzumab ozogamicin.

Main Methods:

  • Review of current literature on MoAb therapies for AML.
  • Analysis of the mechanism of action and resistance pathways for gemtuzumab ozogamicin.

Main Results:

  • Gemtuzumab ozogamicin, an anti-CD33 antibody linked to calicheamicin, is a highly effective AML treatment.
  • P-glycoprotein-mediated MDR can reduce calicheamicin's efficacy by pumping it out of leukemia cells.

Conclusions:

  • Gemtuzumab ozogamicin is a significant advancement in AML treatment.
  • Combination therapy with MDR modifiers presents a promising strategy to improve gemtuzumab ozogamicin's effectiveness in AML patients.

Related Experiment Videos